Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quintiles Draws Curtain On Phase I India Unit As External Business Environment Gets Challenging

This article was originally published in PharmAsia News

Executive Summary

The leading CRO shutters its Phase I unit in Hyderabad inaugurated only two years ago. The decision signifies the tough regulatory challenges global companies are facing in India.

You may also be interested in...

Quintiles IPO Points To Increased Pharma Productivity And Outsourcing

Slated for May 9, this offering for the largest CRO is expected to attract a wide range of investors, including health care specialists and growth-oriented generalists. The IPO filing shows how the biopharma industry is rebounding. But the CRO’s risk-sharing projects with pharma, which gained attention in recent years, don’t seem to be that productive.

Change Of Guard At Quintiles India As Company Continues Aggressive Asia Efforts With Samsung Deal

MUMBAI - Quintiles Transnational Corp.'s India CEO Ferzaan Engineer will step down after serving the multinational contract research organization since its inception in India more than 13 years ago

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts